Hyperglycaemia and the SOAR stroke score in predicting mortality by McCall, Stephen et al.
1 
 
Hyperglycaemia and the SOAR stroke score in predicting 
mortality 
Highlight title: Prognostic value of hyperglycaemia in stroke  
 
Stephen J. McCall1,2 *; Turkiah A. Alanazi1 *; Allan B. Clark3;   Stanley D. Musgrave3;Joao 
H. Bettencourt-Silva3;Max O. Bachmann3; Anthony K. Metcalf4; Kristian M. 
Bowles3,4;Mamas A. Mamas5,6; John F. Potter DM3,4; Phyo K. Myint1,3 
1Ageing Clinical & Experimental Research Group, Institute of Applied Health Sciences, 
University of Aberdeen, UK 
2Nuffield Department of Population Health, University of Oxford, Oxford, UK 
3Norwich Medical School, University of East Anglia, UK 
4Norfolk and Norwich University Hospital, Norwich, UK 
5Cardiovascular Research Group, Institutes of Science and Technology in Medicine and 
Primary Care and Health Sciences, Keele University, Stoke-on-Trent, UK 
6Farr Institute, University of Manchester, Manchester, UK 
 
Stephen J. McCall, Research Associate 
Turkiah A. Alanazi, Research Affiliate 
Allan B. Clark, Senior Lecturer in Medical Statistics 
Stanley D. Musgrave, Senior Research Associate 
Joao H. Bettencourt-Silva, Research Associate 
Max O. Bachmann, Professor of Health Services Research 
Anthony K. Metcalf, Consultant Stroke Physician 
Kristian M. Bowles, Professor of Haematology 
Mamas A. Mamas, Professor of Cardiology 
John F. Potter, Professor of Ageing & Stroke Medicine 
Phyo K. Myint, Professor of Medicine of Old Age 
Address for correspondence: Professor Phyo Kyaw Myint, Room 4:013 Polwarth Building, 
School of Medicine, Medical Sciences & Nutrition, University of Aberdeen, Foresterhill, 
Aberdeen, AB25 2ZD, UK. Tel: +44 (0) 1224 437841, Fax: +44 (0) 1224 437911,  
Email: phyo.myint@abdn.ac.uk 
*Joint first authors 
Word count: 2105 (text excl. abstract and tables) 
 
 
 
2 
 
Abstract  
Background: We assessed the association between admission blood glucose levels and acute 
stroke mortality and examined if there was any incremental value of adding glucose status to 
the validated acute stroke mortality predictor - the SOAR score. 
Methods: Data from Norfolk and Norwich University Hospital Stroke & TIA register (2003-
2013) and Anglia Stroke Clinical Network Evaluation Study (2009-2012) were analysed.  
Multivariable analysis assessed the association between admission blood glucose levels with 
inpatient and 7-day mortality.  The prognostic ability of the SOAR score was then compared 
with the SOAR with glucose score(SOAR-G).  
Results: A total of 5,575 acute stroke patients(ischaemic stroke 89.2%), with mean age(sd) 
of 76.97±11.88 years were included. Both borderline hyperglycaemia(7.9-11.0mmol/L) and 
hyperglycaemia(>11.0mmol/L) when compared to normoglycaemia(4.0-7.8mmol/L), were 
associated with both 7-day and inpatient mortality after controlling for sex, age, OCSP 
classification and pre-stroke modified Rankin score. Both the SOAR stroke score and SOAR-
G were good predictors of inpatient stroke mortality[AUC 0.82(95%CI:0.81-0.84) and 
0.83(95%CI:0.81-0.84)], respectively. These scores were also good at predicting outcomes in 
both patients with and without diabetes. 
Conclusions: High blood glucose levels at admission were associated with worse acute 
stroke mortality outcomes.  The constituents of the SOAR stroke score were good at 
predicting mortality after stroke.   
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Key points 
• A borderline hyperglycaemic score and a high SOAR score had an increased 
likelihood of acute stroke mortality. 
• The addition of hyperglycaemia did not improve the prognostic ability of the SOAR 
score 
• The constituents of the SOAR stroke score are good at predicting poor outcomes after 
stroke without the addition of glucose.   
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Abbreviations: 
aOR: adjusted odds ratio  
ASCNES: Anglia Stroke Clinical Network Evaluation Study 
AUC: area under the curve 
mRS: modified Rankin score 
LACS: lacunar stroke; 
NNSTR: Norfolk and Norwich University Hospitals Stroke and Transient Ischaemic Attack register 
NNUH: Norfolk and Norwich University Hospitals Stroke 
PACS: partial anterior circulation stroke 
POCS: posterior circulation stroke 
OCSP: Oxford Community Stroke Project 
SOAR: Stroke subtype, Oxford Community Stroke Project classification, Age, and prestroke modified 
Rankin score. 
SOAR-G: Stroke subtype, Oxford Community Stroke Project classification, Age, prestroke modified 
Rankin score and glucose.  
TACS: total anterior circulation stroke 
TIA: Transient Ischaemic Attack  
ROC: receiver operating characteristic   
uOR: unadjusted odds ratio 
 
4 
 
Introduction 
Hyperglycaemia after acute stroke has a prevalence ranging of 8-20% with many patients 
having previously diagnosed diabetes mellitus.  [1,2]  Observational evidence suggests that 
hyperglycaemia following stroke is strongly associated with poor outcomes and limited 
neurological recovery. [3]  
Scoring systems comprising of simple, easily assessable factors following stroke have been 
shown to be useful in predicting stroke mortality and length of hospital stay. [4-7]  We have 
previously developed a simple indicator - SOAR Stroke Score, [8]  which has been shown to 
accurately predict acute stroke mortality and length of stay by external validation work. [6,9]  
The original SOAR score did not include glucose in its calculation. However, the Get with 
the Guidelines-Stroke investigators have included a presence of diabetes mellitus in the 
calculation of their prediction score. [4]  Furthermore, the addition of hyperglycaemia to the 
IScore improved the score’s ability to predict 30-day and 1-year mortality after an acute 
ischaemic stroke. [5]   
We are therefore interested in whether including blood glucose status as an additional 
criterion in the SOAR stroke score would improve the prognostic accuracy. Therefore, the 
aims of this study were firstly to examine the independent association between blood glucose 
levels at admission and acute stroke mortality outcomes at 7-days. Secondly, to assess 
whether adding glucose status to the SOAR score would improve the ability of the SOAR 
score in predicting 7-day and inpatient mortality. We also considered it important to assess 
the predictive ability of these scores in patients with and without diabetes mellitus.     
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Material and methods 
The stroke cases included in this study were drawn from two datasets, Norfolk and Norwich 
University Hospitals (NNUH) Stroke and Transient Ischaemic Attack (TIA) register 
(NNSTR) and the Anglia Stroke Clinical Network Evaluation Study (ASCNES). Both of 
these datasets have been previously described. [9-13] Briefly, NNUH Stroke and TIA register 
was set up in 1996 and has a catchment population of ~750,000. These data were obtained 
from both paper-based and electronic records, rigorous data entry checks ensured accuracy. 
[10-12]  The study rationale, aims and methods of the ASCNES have been previously 
reported. [13,14]  In brief, this study used routinely collected data from eight specified 
months between October 2009 and September 2011 and had a one-year follow up of the 
included patients. The ASCNES collected data from eight acute stroke services from eight 
NHS Trusts in East of England with a catchment population of ~2.5 million. For calculation 
of SOAR stroke score, the pre-stroke modified Rankin score (mRS) at admission was 
extracted from medical records of each patient or was assessed by gaining information from 
relatives. Admission, discharge dates and mortality status were collected from the acute 
stroke unit, from which acute hospital stay was obtained. 
For both study populations, the patient’s medical history, CT or MRI scans were used to 
ascertain cases of ischaemic and haemorrhagic stroke. TIA, subdural hematoma and 
subarachnoid haemorrhages were specifically excluded from the study.  As ASCNES 
included NNUH patients (8 study months between 2009 and 2011) to avoid duplication of 
results any patient who had a duplicate record, one of the records (from NNSTR as a default) 
was excluded from the current study. For those with recurrent strokes, their first occurrence 
of stroke was included in the study. 
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SOAR score 
The SOAR score is an eight point score ranging from score 0-7, which comprises of Stroke 
subtype (haemorrhagic/ischaemic), Oxford Community Stroke Project classification, Age, 
and prestroke modified Rankin Score. [8, 9] Glucose levels on admission was added to the 
SOAR score as a criterion which scores 1 point; the SOAR-G score ranged from 0-8 and 
gave a person with an abnormal glucose score (either borderline hyperglycaemia or 
hyperglycaemia) an additional point in the scoring system. The calculation of the new score 
(SOAR-G) is described in Supplementary Table 1.  
Statistical Analysis 
The main exposure of interest was blood glucose levels at admission. The former was 
categorized into four categories using standard cut off points, hypoglycaemia (<4.0mmol/L), 
normoglycemia (4.0-7.8mmol/L), borderline hyperglycaemia (7.9-11.0mmol/L) and 
hyperglycaemia (≥11.1mmol/L).  [15]  Only stroke cases with complete data to calculate 
SOAR and no missing data for admission glucose were included in the current study. The 
outcomes of interest were 7-day mortality and inpatient mortality. Inpatient mortality 
included any deaths that occurred during the same admission. 7-day mortality included all 
deaths within 7 days of hospital admission and status at discharge did not impact inclusion 
into this outcome. 
 Data analyses were performed using SPSS V.22.0 (Chicago, Illinois, USA). Unconditional 
logistic regression models were constructed for both inpatient and 7-day mortality outcomes. 
This model adjusted for sex, age categories (≤60, 61–79, ≥80), Oxford Community Stroke 
Project (OCSP) classification (total anterior circulation stroke (TACS), lacunar stroke 
(LACS), posterior circulation stroke (POCS) and partial anterior circulation stroke (PACS)), 
pre-stroke mRS (0-5), diabetes status prior to diagnosis and stroke type (ischaemic or 
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haemorrhagic). Sex was assessed as a confounder in the multivariable regression and there 
were no data available on ethnicity but majority were white Caucasians (>99.5%). Using the 
multivariable model, a sensitivity analysis was completed treating admission blood glucose 
as a continuous variable. Further models were created by stratifying the initial models by 
stroke type (haemorrhagic and ischaemic stroke types) for both outcomes. Complete case 
analysis was used to address missing data.  
The discriminating ability of SOAR and SOAR-G was compared using receiver operating 
characteristic (ROC) curves; a combined command was used to assess the equality each of 
the curves from each score using area under the curve (AUC). A sensitivity analysis was 
completed; this entailed stratifying each of the ROC curves by diabetes status. These have 
been presented as area under the curve (AUC) from the ROC curves. STATA V.13SE 
(STATA Corp, Texas, USA) was used for the ROC curve analysis.   
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Results 
I) Study population characteristics 
The potentially eligible sample consisted of 4,825 patients from the NNSTR and 1,766 
patients from the ASCNES; 74 patients had missing discharge status data. A further 116 
patients had missing glucose data on admission and 826 patients had other missing clinical or 
demographic data. As shown in figure 1, this provided a total of 5,575 patients eligible to be 
included in the study.  The sample characteristics are shown in Table 1. The sample mean(sd) 
age was 76.96 ± 11.8 years, with 48.6% males. Of the whole group 89.2% had an ischaemic 
stroke and 60.4% had a pre-stroke mRS of 0 (i.e. fully independent).  The most common 
OCSP stroke classification was partial anterior circulation stroke (PACS) with 36.1% of 
patients. The majority (74.1%) of patients had a normal glucose level on admission with 
20.7% of patients known to have diabetes. 18% of the study subjects died as inpatient and 
8.4% died within 7-days of admission. The median length of stay was 8 days (IQR 4-18) and 
the range was 0-180 days. 
II) Glucose level and mortality after stroke 
In a multivariate analysis including all stroke types, those with borderline hyperglycaemia, 
compared to those with normal glucose levels, had an increased likelihood of inpatient 
mortality with an adjusted odds ratio (aOR) of 1.93 (95%CI: 1.57-2.37)) and 7-day mortality 
with an aOR of 2.18 (95% CI: 1.70-2.80)). The likelihood of inpatient and 7-day mortality 
was not significantly higher for hyperglycaemia versus normoglycaemia (aOR: 2.64 (95%CI: 
1.98-3.54) vs. aOR: 3.6 (95%CI: 2.61-5.17), respectively).  
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III) Glucose level and mortality after stroke by stroke type 
A similar trend was evident for both mortality outcomes when the analysis was stratified by 
stroke sub-type. The impact on inpatient mortality by having hyperglycaemia compared to a 
normal glucose level on admission appeared to be greater for haemorrhagic stroke than for 
ischaemic stroke (aOR 4.92 (95% CI: 2.47-9.77) vs. aOR 2.32 (1.68-3.22)). There was a 
similar trend for the 7-day mortality outcome. In a sensitivity analysis, the adjusted odds of 
inpatient mortality increased by 11% per each additional unit increase in glucose level at 
admission (aOR: 1.11 (95% CI: 1.08 - 1.14)). Similarly, the adjusted odds of 7-day mortality 
increased by 12% per unit increase in glucose level at admission (aOR: 1.12 (95%  CI:1.09-
1.16)).              
IV) SOAR, SOAR-G and mortality outcomes 
The overall discriminating value for each SOAR score and mortality outcome is presented in 
supplementary Table 2. Both the SOAR and SOAR-G scores were highly predictive in 
discriminating inpatient mortality with an AUC of 0.82 (95% CI: 0.81-0.84) and 0.83 (95% 
CI: 0.81-0.84), respectively (See Table 3). Similarly, the SOAR and SOAR-G scores were 
highly predictive in discriminating 7-day mortality with an AUC of 0.80 (95% CI: 0.78-0.82) 
and 0.82 (95% CI: 0.80-0.84), respectively (See Figures 2a-b). For both outcomes, in the 
combined analysis, despite a minimal absolute increase in the AUC between the SOAR and 
SOAR-G scores there was a statistical difference in the predictive ability between the scores, 
with SOAR-G performing better than SOAR.  
V) Prognostics values stratified by diabetes status 
Figures 2c-1f highlights the ROC curve analysis stratified by diabetes status. The SOAR 
score had very similar predictive abilities when stratified by diabetes diagnosis status, in both 
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respective outcomes. The SOAR score including glucose had very similar predictive abilities 
when stratified by diabetes diagnosis status, in both respective outcomes. 
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Discussion 
Study summary 
In this study, we confirmed that SOAR stroke score was highly predictive of both inpatient 
and 7-day mortality. Whilst admission glucose level was an independent predictor of early 
stroke mortality, addition of glycaemic status to SOAR stroke score did not bring clinically 
meaningful benefit despite the score’s discriminating ability being improved statistically. 
When this analysis was stratified by diabetes status, both SOAR scores were good at 
predicting stroke outcomes in both patients with diabetes and patients without diabetes.  
Findings in context of literature – glucose and stroke outcome 
Our study findings are in consistent with much of the previous literature, as a number of 
studies have shown a strong association between hyperglycaemia and poor stroke outcome. 
[16-20]   Similar to previous research, this study illustrates that there was a linear association 
between increased glucose levels and post stroke mortality. [16] Despite this association, 
there remains debate around the causal relationship between glucose and post stroke 
outcome. A Cochrane review has shown that there was no evidence to support benefit in 
maintaining blood glucose at a range of 4-7.5mmol/L after stroke; the main outcomes studied 
in this system review were death, functionality and neurological deficit. [21]  
Findings in context of literature – prognostic score 
Despite a statistically significant difference between SOAR and SOAR-G scores, the addition 
of SOAR with glucose is unlikely to be useful in clinical practice as the improvement in 
score performance is minimal despite the statistical significance.  Stratifying upon diabetes 
status did not change the predictive ability of the either SOAR score. The most recent 
Cochrane Review suggested that there is no specific blood glucose threshold that must be 
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maintained in patients with hyperglycaemia after an acute stroke. [21] This illustrates that the 
constituents of the SOAR score already contain the informative predictors of poor outcomes 
after a stroke. 
The purposes of this study were to assess whether in our population, glucose level after 
stroke was associated with poor outcomes and if so whether the addition of glycaemic status 
to the SOAR stroke score improved its prognostic ability. As this association existed we 
further assessed whether it would improve the predictive ability of an established SOAR 
stroke score. The data from our study suggests that although an increase in glucose level was 
associated with mortality it did not materially change the predictive ability of the SOAR 
score.  
Strengths and weaknesses 
 Our prospectively collected study had a relatively large and representative sample using the 
data from multiple centres across the East Anglia. The SOAR score itself is very easy to 
obtain and calculate, unlike other prognostic measures, this makes it a very practical measure 
to use in a clinical setting. [6,8]  As this was an observational study, it cannot imply the 
causal relationship between glucose and stroke outcome. The use of data from hospital-based 
registries may be a potential limitation of this study as severe strokes that resulted in death in 
the community were not included in the registry, similarly mild strokes may have not 
attended secondary care. [8]  However, the truncation of distribution will only attenuate the 
observed associations. Further prognostic information of mortality is irrelevant to those who 
died prior to admission and those who sustained mildest forms of stroke with almost 0% 
chance of mortality from the event.  [8,22]   
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Conclusion 
To conclude, we have shown that both SOAR stroke score and SOAR with glucose score 
were very good at predicting both inpatient and 7-day mortality after an acute stroke. 
Although there was a statistically significant difference between the scores, the added value 
of including glucose to the SOAR did not clinically increase its discriminating ability in an 
unselected stroke patient population.  
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Table & Figure Legends 
 
 
Table 1: The overall sample characteristics of the combined ASCNES and NNUH datasets 
 
Table 2:   Multivariate analysis examining the risk of mortality for glucose levels and patient 
characteristics by all stroke types, ischaemic and haemorrhagic strokes.  
 
 
Table 3: The predictive ability of the SOAR scores for mortality outcomes: using receiving 
operating characteristic curves. 
Figure 1. Derivation of study population 
 
Figure 2a. Receiver Operating Characteristic curve differentiating inpatient mortality using SOAR and 
SOAR with glucose score 
 
 Figure 2b. Receiver Operating Characteristic curve differentiating 7-day mortality using SOAR and 
SOAR with glucose score 
 
Figure 2c. Receiver Operating Characteristic curve differentiating inpatient mortality using SOAR and 
stratified by diabetes status before diagnosis 
 
 Figure 2d. Receiver Operating Characteristic curve differentiating inpatient mortality using SOAR 
with glucose score stratified by diabetes status before diagnosis 
 
Figure 2e. Receiver Operating Characteristic curve differentiating 7-day mortality using SOAR and 
stratified by diabetes status before diagnosis 
 
 Figure 2f. Receiver Operating Characteristic curve differentiating 7-day mortality using SOAR with 
glucose score stratified by diabetes status before diagnosis 
 
Supplementary Table 1. Scoring system for SOAR-G index 
 
Supplementary Table 2. The predictive ability of the SOAR stroke score and SOAR stroke score with 
glucose for both inpatient and 7 day mortality. 
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Supplementary Table 1. Scoring system for SOAR-G index 
Patient Variables Score Variable Score 
Age 
categories 
≤60 0 
Pre-
stroke 
mRS 
0 0 
61–65 0 1 0 
66–70 1 2 0 
71–75 1 3 1 
76–80 1 4 1 
81–85 1 5 2 
86–90 2     
 91+ 2     
OCSP 
classification 
TACS 2 
Glucose 
level 
Normal 0 
PACS 0 Hypoglycaemia 0 
LACS 0 Borderline hyperglycaemia 1 
POCS 1 Hyperglycaemia 1 
         
Stroke type 
Infarct 0 
Gender 
Male 0 
Haemorrhage 1 Female 0 
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Supplementary Table 2 The predictive ability of the SOAR stroke score and SOAR stroke score with glucose for both in-patient and 7 day mortality.  
In-patient mortality 
SOAR Score Sensitivity 95% CI Specificity 95% CI Positive predictive value 95% CI Negative predictive value 95% CI 
0 99.5 98.84 99.84 9.9 9.05 10.8 19.43 18.35 20.54 98.91 97.47 99.64 
≥1 89.79 87.74 91.6 51.2 49.74 52.66 28.66 27.08 30.28 95.83 94.96 96.59 
≥2 76.18 73.41 78.79 77.78 76.54 78.97 42.8 40.49 45.14 93.73 92.91 94.48 
≥3 45.85 42.72 48.99 93.27 92.5 93.98 59.79 56.22 63.29 88.75 87.82 89.63 
≥4 15.82 13.61 18.23 98.3 97.88 98.65 66.95 60.55 72.92 84.25 83.24 85.22 
≥5 3.3 2.28 4.61 99.65 99.43 99.8 67.35 52.46 80.05 82.52 81.49 83.51 
≥6 -   -   -   -    
7_Day mortality 
0 99.15 97.84 99.77 8.89 8.13 9.71 9.11 8.33 9.93 99.13 97.78 99.76 
≥1 91.49 88.59 93.85 47.11 45.73 48.49 13.74 12.55 14.99 98.36 97.78 98.83 
≥2 77.87 73.84 81.55 72.34 71.09 73.56 20.58 18.73 22.54 97.26 96.69 97.76 
≥3 48.72 44.12 53.34 89.48 88.61 90.31 29.9 26.67 33.28 94.99 94.33 95.59 
≥4 17.87 14.51 21.64 97.02 96.52 97.47 35.59 29.49 42.06 92.77 92.04 93.45 
≥5 3.62 2.12 5.73 99.37 99.12 99.57 34.69 21.67 49.64 91.8 91.05 92.51 
≥6 -   -   -   -    
Inpatient mortality 
SOAR + Glucose Score Sensitivity 95% CI Specificity 95% CI Positive predictive value 95%CI Negative predictive value 95% CI 
0 99.6 98.98 99.89 7.89 7.12 8.71 19.1 18.04 20.19 98.9 97.22 99.7 
≥1 92.59 90.79 94.14 42.77 41.33 44.22 26.1 24.66 27.58 96.36 95.45 97.13 
≥2 81.28 78.72 83.66 71.74 70.41 73.05 38.57 36.49 40.69 94.61 93.81 95.34 
≥3 57.86 54.73 60.94 89.84 88.93 90.7 55.42 52.34 58.46 90.71 89.83 91.54 
≥4 28.83 26.04 31.75 96.96 96.42 97.44 67.45 62.78 71.87 86.19 85.22 87.12 
≥5 8.61 6.94 10.52 99.21 98.91 99.45 70.49 61.56 78.4 83.26 82.24 84.24 
≥6 1.4 0.77 2.34 99.93 99.81 99.99 82.35 56.57 96.2 82.28 81.25 83.27 
≥7 -   -   -   -    
7-Day mortality 
0 99.36 98.15 99.87 7.09 6.4 7.83 8.96 8.2 9.77 99.18 97.62 99.83 
≥1 93.83 91.26 95.83 39.22 37.87 40.57 12.44 11.37 13.58 98.57 97.96 99.04 
≥2 84.04 80.41 87.24 66.5 65.19 67.8 18.76 17.12 20.5 97.84 97.3 98.3 
≥3 62.34 57.79 66.74 85.31 84.31 86.27 28.09 25.38 30.93 96.09 95.49 96.64 
≥4 34.04 29.76 38.52 94.77 94.12 95.36 37.47 32.86 42.25 93.98 93.29 94.61 
≥5 10.43 7.81 13.55 98.57 98.21 98.88 40.16 31.39 49.42 92.28 91.54 92.97 
≥6 1.91 0.88 3.6 99.84 99.69 99.93 52.94 27.81 77.02 91.71 90.95 92.42 
≥7 -     -     -     -     
 
Figure 1. Derivation of study population  
 
Figure 2a. Receiver Operating Characteristic curve differentiating inpatient mortality using SOAR 
and SOAR with glucose score   
 
 
Figure 2b. Receiver Operating Characteristic curve differentiating 7-day mortality using SOAR and 
SOAR with glucose score  
 
 
 
 
Figure 2c. Receiver Operating Characteristic curve differentiating inpatient mortality using SOAR 
and stratified by diabetes status before diagnosis 
 
 
Figure 2d. Receiver Operating Characteristic curve differentiating inpatient mortality using SOAR 
with glucose score stratified by diabetes status before diagnosis 
 
 
 
 
Figure 2e. Receiver Operating Characteristic curve differentiating 7-day mortality using SOAR and 
stratified by diabetes status before diagnosis 
 
 
Figure 2f. Receiver Operating Characteristic curve differentiating 7-day mortality using SOAR with 
glucose score stratified by diabetes status before diagnosis  
 
 
Table 1. The overall sample characteristics of the combined ASCNES and NNUH datasets.   
Total sample  n 
(%) 
Death     n 
(%) 
7 Day 
mortality n 
(%) 
   
n=999 n=470 
Age category  ≤60 years 538 (9.7) 27 (2.7) 24 (5.1) 
61–79 years  2303 (41.3) 263 (26.3) 140 (29.8) 
>79 years 2734 (49) 709 (71.0) 306 (65.1) 
     
Sex Male 2707 (48.6) 407 (59.3) 270 (57.4) 
Female 2868 (51.4) 592 (40.7) 200 (42.6) 
     
Stroke type Ischaemic  4974 (89.2) 790 (79.1) 331 (70.4) 
Haemorrhage 601 (10.8) 209  (20.9) 139 (29.6) 
     
OCSP classification TACS 1202 (21.6) 619 (62.0) 317 (67.4) 
PACS 2015 (36.1) 196 (19.6) 56 (11.9) 
LACS 1405 (25.2) 50 (5.0) 18 (3.8) 
POCS 953 (17.1) 134 (13.4) 79 (16.8) 
     
Pre-stroke mRS 0 3366 (60.4) 447 (44.7) 240 (51.1) 
1 747 (13.4) 140 (14.0) 62 (13.2) 
2 529 (9.5) 111 (11.1) 52 (11.1) 
3 527 (9.5) 140 (14.0) 50 (10.6) 
4 282 (5.1) 109 (10.9) 46 (9.8) 
5 124 (2.2) 52 (5.2) 20 (4.3) 
     
Random plasma glucose 
level 
 
Hypoglycaemia (<4.0mmol/L) 51 (0.9) 7 (0.7) 3 (0.6) 
Normal (4.0-7.8mmol/L), 4132 (74.1) 595 (59.6) 245 (52.1) 
Borderline hyperglycaemia (7.9-
11.0mmol/L) 
918 (16.5) 264 (26.4) 142 (30.2) 
Hyperglycaemia (≥11.1mmol/L) 474 (8.5) 133 (13.3) 80 (17.0) 
     
Diabetes before diagnosis  No 4420 (79.3) 790 (79.1) 382 (81.3) 
Yes 1155 (20.7) 209 (20.9) 88 (18.7) 
TACS, total anterior circulation stroke; PACS, partial anterior circulation stroke; POCS, posterior circulation stroke; LACS, 
lacunar stroke; mRS, modified Rankin score; OCSP, Oxford Community Stroke Project. 
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Table 2.   Multivariate analysis examining the risk of mortality for glucose levels and patient characteristics by all stroke types, ischemic and haemorrhagic strokes.  
     Inpatient death Early death Within 7 days 
Both stroke types OR  95% CI P OR  (95% CI) P 
Glucose level 
Normal 1    1   
Hypoglycaemia 0.99 [0.39-2.53] 0.99 1.29 [0.36-4.60] 0.69 
Borderline 
hyperglycaemia 1.93 [1.57-2.37] <0.001 2.18 [1.70-2.80] <0.001 
Hyperglycaemia 2.64 [1.98-3.54] <0.001 3.67 [2.61-5.17] <0.001 
Haemorrhagic stroke             
Glucose level 
Normal 1   1   
Hypoglycaemia 3.32 [0.08-143.26] 0.53 - - - 
Borderline 
hyperglycaemia 2.9 [1.75-4.79] <0.001 3.09 [1.86-5.13] <0.001 
Hyperglycaemia 4.92 [2.47-9.77] <0.001 5.6 [2.80-11.20] <0.001 
Ischemic stroke   
Glucose level 
Normal 1   1   
Hypoglycaemia 0.9 [0.34-2.40] 0.83 1.56 [0.44-5.49] 0.49 
Borderline 
hyperglycaemia 1.76 [1.40-2.21] <0.001 1.95 [1.45-2.61] <0.001 
Hyperglycaemia 2.32 [1.68-3.22] <0.001 3.33 [2.23-4.96] <0.001 
Adjusted for sex, age, pre-stroke mRS, OSCP classification, diabetes before diagnosis, stroke type(excluding stratified models). 
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Table 3.  The predictive ability of the SOAR scores for mortality outcomes: using receiving operating 
characteristic curves.  
 
Outcome Prognostic score 
Area under the 
curve 95% Confidence Interval P-value 
Inpatient mortality 
SOAR  0.82 (0.807-0.836) 0.027 
SOAR with glucose 0.83 (0.813-0.841) 
     
7-day mortality 
SOAR 0.80 (0.783-0.822) <0.001 
SOAR with glucose 0.82 (0.797-0.836) 
 
 
